0 480

Cited 7 times in

Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy

DC Field Value Language
dc.contributor.author김주항-
dc.contributor.author김혜련-
dc.contributor.author박형순-
dc.contributor.author이민구-
dc.contributor.author조병철-
dc.contributor.author조응혁-
dc.date.accessioned2017-02-24T03:21:23Z-
dc.date.available2017-02-24T03:21:23Z-
dc.date.issued2016-
dc.identifier.issn1744-6872-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/146322-
dc.description.abstractBACKGROUND: Genetic polymorphisms contribute toward interindividual variations in drug response. We investigated the effects of genetic polymorphisms on the clinical outcome of advanced non-small-cell lung cancer patients with first-line paclitaxel and carboplatin. MATERIALS AND METHODS: A total of 194 non-small-cell lung cancer patients were prospectively enrolled from January 2010 to January 2013. We genotyped 11 polymorphisms in seven genes involved in the glycolysis pathway and the related pharmacokinetic/pharmacodynamic pathway. Genetic associations with PET-SUV, survival outcome, and toxicity were analyzed, and in-vitro drug transport activity was measured in the oocyte system. RESULTS: Patients with the c.334 T>G and c.699 G>A homozygous variant in SLCO1B3 showed a higher incidence of grade 3/4 anemia (P=0.002). Transport activities of oocyte that overexpress the SLCO1B3 c.699 G>A variant showed a significantly decreased uptake of paclitaxel compared with the wild-type expressing oocytes. In addition, patients with GG/GA/AA genotypes of ABCB1, c.2677 T>G/A locus showed inferior progression-free survival (hazard ratio=1.49, P=0.017) compared with other genotypes. The GA genotype of HIF1A, c.1834 G>A locus was associated with inferior progression-free survival compared with the GG genotype (hazard ratio=2.47, P=0.008). CONCLUSION: This study showed that the SLCO1B3 c.699 G>A polymorphism may predict anemia and ABCB1, HIF1A polymorphism are highly predictive for worse survival in advanced NSCLC with first-line paclitaxel and carboplatin.-
dc.description.statementOfResponsibilityrestriction-
dc.format.extent116~125-
dc.languageEnglish-
dc.publisherLippincott Williams & Wilkins-
dc.relation.isPartOfPHARMACOGENETICS AND GENOMICS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHATP Binding Cassette Transporter, Sub-Family B/genetics-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols-
dc.subject.MESHCarboplatin/administration & dosage*-
dc.subject.MESHCarboplatin/therapeutic use-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/drug therapy*-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/genetics-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/mortality-
dc.subject.MESHFemale-
dc.subject.MESHGlycolysis/drug effects-
dc.subject.MESHHumans-
dc.subject.MESHHypoxia-Inducible Factor 1, alpha Subunit/genetics*-
dc.subject.MESHLung Neoplasms/drug therapy*-
dc.subject.MESHLung Neoplasms/genetics-
dc.subject.MESHLung Neoplasms/mortality-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOrganic Anion Transporters, Sodium-Independent/genetics*-
dc.subject.MESHPaclitaxel/administration & dosage*-
dc.subject.MESHPaclitaxel/therapeutic use Polymorphism, Single Nucleotide-
dc.subject.MESHPrognosis-
dc.subject.MESHProspective Studies-
dc.subject.MESHSolute Carrier Organic Anion Transporter Family Member 1B3-
dc.subject.MESHSurvival Analysis-
dc.titlePharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy-
dc.typeArticle-
dc.publisher.locationUnited States-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorHyung Soon Park-
dc.contributor.googleauthorSun Min Lim-
dc.contributor.googleauthorHo Jung Shin-
dc.contributor.googleauthorArthur Cho-
dc.contributor.googleauthorJae-Gook Shin-
dc.contributor.googleauthorMin Goo Lee-
dc.contributor.googleauthorHye Ryun Kim-
dc.contributor.googleauthorJoo Hang Kim-
dc.contributor.googleauthorByoung Chul Cho-
dc.identifier.doi10.1097/FPC.0000000000000196-
dc.contributor.localIdA00945-
dc.contributor.localIdA01166-
dc.contributor.localIdA04576-
dc.contributor.localIdA02781-
dc.contributor.localIdA03822-
dc.contributor.localIdA03887-
dc.relation.journalcodeJ02506-
dc.identifier.eissn1744-6880-
dc.identifier.pmid26641474-
dc.identifier.urlhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=01213011-201603000-00002&LSLINK=80&D=ovft-
dc.subject.keywordnon-small-cell lung cancer-
dc.subject.keywordpaclitaxel-
dc.subject.keywordpolymorphism-
dc.subject.keywordSLCO1B3-
dc.subject.keywordsurvival-
dc.subject.keywordtoxicity-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNameKim, Hye Ryun-
dc.contributor.alternativeNamePark, Hyung Soon-
dc.contributor.alternativeNameLee, Min Goo-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.alternativeNameCho, Arthur Eung Hyuck-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorKim, Hye Ryun-
dc.contributor.affiliatedAuthorPark, Hyung Soon-
dc.contributor.affiliatedAuthorLee, Min Goo-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.contributor.affiliatedAuthorCho, Arthur Eung Hyuck-
dc.citation.volume26-
dc.citation.number3-
dc.citation.startPage116-
dc.citation.endPage125-
dc.identifier.bibliographicCitationPHARMACOGENETICS AND GENOMICS, Vol.26(3) : 116-125, 2016-
dc.date.modified2017-02-24-
dc.identifier.rimsid53114-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.